Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China

Fineline Cube Mar 30, 2026
Company Deals

China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio

Fineline Cube Mar 30, 2026
Company Deals

Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic

Fineline Cube Mar 30, 2026
Company Deals

Novartis to Acquire Excellergy for Up to $2 Billion, Adding Next-Gen Anti-IgE Antibody Exl-111 to Immunology Pipeline

Fineline Cube Mar 30, 2026
Company Deals

Huahai Pharma and Almirall Strike $340M Monoclonal Antibody Licensing Deal Targeting Dermatology and Beyond

Fineline Cube Mar 30, 2026
Policy / Regulatory

China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years

Fineline Cube Mar 26, 2026
Company Drug

Hansoh Pharma’s Uplizna Gains Third NMPA Approval in China for Generalized Myasthenia Gravis, Expanding CD19 Antibody Franchise

Fineline Cube Mar 30, 2026
Company Drug

Huadong Medicine’s YY001 Becomes World’s First Recombinant Botulinum Toxin Approved in China for Glabellar Lines

Fineline Cube Mar 30, 2026
Company Deals Drug

Bioray Biopharmaceutical Expands to Turkey with Three Key Drugs, Marking International Milestone

Fineline Cube Mar 31, 2025

Zhejiang Bioray Biopharmaceutical Co., Ltd. announced on March 31 that it has reached a collaboration...

Company

EClinCloud Secures New Funding to Accelerate AI Innovation in Clinical Research

Fineline Cube Mar 30, 2025

EClinCloud (Ningbo) Technology Co., Ltd., a leading AI technology company specializing in clinical research solutions,...

Medical Device Policy / Regulatory

China Tightens Medical Device Quality Oversight: 2025 Inspection Plan Unveiled

Fineline Cube Mar 29, 2025

China’s National Medical Products Administration (NMPA) has released its 2025 medical device inspection plan, outlining...

Policy / Regulatory

Policy Analysis: Shanghai’s 2025 Pharmaceutical Procurement Regulation and Market Implications

Fineline Cube Mar 29, 2025

Shanghai’s Medical Centralized Bidding and Procurement Affairs Management Office has released its January 2025 list...

Policy / Regulatory

Guangdong Accelerates Centralized Procurement for Apixaban and Key Therapeutics

Fineline Cube Mar 29, 2025

The Guangdong Drug Trading Center has issued a critical update on preparations for the centralized...

Medical Device Policy / Regulatory

China Unveils 2025 Medical Device Inspection Strategy to Tighten Quality Control

Fineline Cube Mar 29, 2025

China’s National Medical Products Administration (NMPA) convened a pivotal conference in Chengdu on March 24...

Company Deals Drug

Eisai Transfers Pariet Rights in China to CBC Group-Controlled Peak Pharma

Fineline Cube Mar 29, 2025

Japan-based Eisai (TYO: 4523) announced a strategic decision to transfer the rights of its proton...

Company Drug

Sinovac Biotech’s SNA02-48 Gains Clinical Approval for Tetanus Prevention

Fineline Cube Mar 29, 2025

Beijing Sinovac Biotech Co., Ltd’s (NASDAQ: SVA) subsidiary Sinovac Life Sciences Co., Ltd. and its...

Policy / Regulatory

Shanghai Designates Backup Suppliers and Specialized Drug Formulations in GY-YD2024-2 Procurement

Fineline Cube Mar 29, 2025

Shanghai has finalized its list of second-tier backup suppliers and manufacturers for specialized drug formulations...

Company Medical Device

Abbott Laboratories’ Volt PFA System Receives EU CE Mark for Atrial Fibrillation Treatment

Fineline Cube Mar 28, 2025

US-based Abbott Laboratories (NYSE: ABT) has announced the receipt of the CE mark in the...

Company Deals

Alcon Laboratories Acquires Majority Stake in Aurion Biotech to Advance Eye Disease Cell Therapy

Fineline Cube Mar 28, 2025

US-based eye care firm Alcon Laboratories, Inc. has announced the acquisition of a majority stake...

Company Drug

Genmab’s Tivdak Approved in Japan for Advanced Cervical Cancer Treatment

Fineline Cube Mar 28, 2025

Denmark-based Genmab A/S (NASDAQ: GMAB) has secured approval from the Japan Ministry of Health, Labour...

Company

CStone Pharmaceuticals Reports 2024 Results with License Fee Growth Offsetting Drug Sales Decline

Fineline Cube Mar 28, 2025

China-based CStone Pharmaceuticals (HKG: 2616) reported its 2024 financial results and recent business highlights. Revenues...

Company Deals Drug

TransThera and Akeso Biopharma Collaborate on HCC Study with Tinengotinib and Bispecific Antibodies

Fineline Cube Mar 28, 2025

Chinese companies TransThera Sciences (Nanjing) Inc. and Akeso Biopharma (HKG: 9926) have formed a strategic...

Company Drug

NMPA Approves Qingfeng’s Suraxavir Marboxil for Influenza A and B Treatment

Fineline Cube Mar 28, 2025

China’s National Medical Products Administration (NMPA) has approved suraxavir marboxil, a Category 1 drug developed...

Company

Medtronic Launches Digital Innovation Base in Beijing’s BioPark

Fineline Cube Mar 28, 2025

US-Irish firm Medtronic (NYSE: MDT) has inaugurated its digital medical innovation base at the BioPark...

Company Drug

Huadong Medicine Gains NMPA Approval for HDM3019 Rheumatoid Arthritis Trial

Fineline Cube Mar 28, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced receiving approval from the National Medical Products...

Company

Lee’s Pharmaceutical Holdings Ltd Reports 32.9% Revenue Growth in 2023

Fineline Cube Mar 28, 2025

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) released its 2023 financial report, recording HKD 1.4...

Company

RemeGen’s 2024 Revenue Soars 58.54% on Strong Product Sales and R&D Growth

Fineline Cube Mar 28, 2025

China-based biotech RemeGen Co., Ltd (HKG: 9995, SHA: 688331) released its 2024 financial report, recording...

Company

JW Therapeutics Sees 9% Revenue Decline in 2024 Amid Commercial Strategy Shift

Fineline Cube Mar 28, 2025

China-based JW Therapeutics (HKG: 2126) released its 2024 financial report, recording RMB 158.2 million (USD...

Posts pagination

1 … 164 165 166 … 643

Recent updates

  • Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China
  • China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio
  • Hansoh Pharma’s Uplizna Gains Third NMPA Approval in China for Generalized Myasthenia Gravis, Expanding CD19 Antibody Franchise
  • Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic
  • Huadong Medicine’s YY001 Becomes World’s First Recombinant Botulinum Toxin Approved in China for Glabellar Lines
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China

Company Deals

China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio

Company Drug

Hansoh Pharma’s Uplizna Gains Third NMPA Approval in China for Generalized Myasthenia Gravis, Expanding CD19 Antibody Franchise

Company Deals

Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.